Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response-Reference-Cited by-同舟云学术

Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response

Published:2013 Issue:5 Volume:59 Page:387-394
ISSN:0009-3157
Container-title:Chemotherapy
language:en
Short-container-title:Chemotherapy

Author:

Kern Peter,Kalisch Anne,Kolberg Hans-Christian,Kimmig Rainer,Otterbach Friederich,von Minckwitz Gunter,Sikov William M.,Pott Dirk,Kurbacher Christian

Publisher

S. Karger AG

Subject

Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer;Expert Review of Anticancer Therapy;2023-10-03

2. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013;npj Breast Cancer;2022-12-30

3. Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy;Frontiers in Oncology;2022-03-17

4. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer;Breast Cancer Research and Treatment;2021-06-26

5. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer;Frontiers in Immunology;2020-03-05